Hot Stocks: Global brokerages see Airtel, Cipla delivering 10-15% return in next 1 year
ICICI Prudential Life received an Equal Weight rating from Morgan Stanley, while Citigroup upheld its Buy rating for Bharti Airtel. Tata Consumer was given a Neutral rating by Goldman Sachs, and Investec maintained a Buy rating for Cipla.
Brokerage Morgan Stanley downgraded ICICI Prudential Life to Equal Weight, Citigroup maintained a buy rating on , Goldman Sachs has a neutral rating in and Investec maintained a buy on .We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Morgan Stanley on ICICI Prudential Life: Equal Weight| Target Rs 610| LTP Rs 593| Upside 3%
Morgan Stanley downgraded ICICI Prudential Life to Equal Weight from Overweight earlier and also slashed the target price to Rs 610 from Rs 660 earlier.
The company reported another quarter with a large miss in VNB margin. It delivered on APE growth, but VNB missed estimate mainly by higher costs.
Higher costs could also be reflected in part in FY25. “The upside to our reduced price target is limited - we move to the sidelines,” said the note.
Citigroup on Bharti Airtel: Buy| Target Rs 1520| LTP Rs 1342| Upside 13%
Citigroup maintained a buy rating on Bharti Airtel and raised the target price to Rs 1520 from Rs 1342 earlier.
The global investment bank hiked FY26 ARPU estimates by 3% and EBITDA by 1-2% for FY25/26 given improved visibility of tariff hikes.
Goldman Sachs on Tata Consumer: Neutral| Target Rs 1030| LTP Rs 1173| Downside 12%
Goldman Sachs maintained a neutral rating on Tata Consumer with a target price of Rs 1030. There is a slowdown in India growth and margins were driven by international and unbranded business.
India business organic growth is weaker than expected. India's beverages business slowed down, partly due to the delayed onset of summer.
EBIT growth is marginally ahead of estimates but driven by international and unbranded business.
Investec on Cipla: Buy| Target Rs 1550| LTP Rs 1347| Upside 15%
Investec maintained a buy rating on Cipla but raised the target price to Rs 1550. Cipla's 10%+ fall from its 52-week high is in anticipation of Amneal's entry into 'albuterol' and a likely weak Q4.
Cipla's dependence on 'albuterol' is low and its impact on EPS is likely to be low.
The global investment bank sees the possibility of upgrades especially for FY25/26 as Cipla delivers key pipeline assets and US Gx macro continues to improve.
(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
Morgan Stanley downgraded ICICI Prudential Life to Equal Weight from Overweight earlier and also slashed the target price to Rs 610 from Rs 660 earlier.
The company reported another quarter with a large miss in VNB margin. It delivered on APE growth, but VNB missed estimate mainly by higher costs.
Higher costs could also be reflected in part in FY25. “The upside to our reduced price target is limited - we move to the sidelines,” said the note.
Citigroup on Bharti Airtel: Buy| Target Rs 1520| LTP Rs 1342| Upside 13%
Citigroup maintained a buy rating on Bharti Airtel and raised the target price to Rs 1520 from Rs 1342 earlier.
The global investment bank hiked FY26 ARPU estimates by 3% and EBITDA by 1-2% for FY25/26 given improved visibility of tariff hikes.
Goldman Sachs on Tata Consumer: Neutral| Target Rs 1030| LTP Rs 1173| Downside 12%
Goldman Sachs maintained a neutral rating on Tata Consumer with a target price of Rs 1030. There is a slowdown in India growth and margins were driven by international and unbranded business.
India business organic growth is weaker than expected. India's beverages business slowed down, partly due to the delayed onset of summer.
EBIT growth is marginally ahead of estimates but driven by international and unbranded business.
Investec on Cipla: Buy| Target Rs 1550| LTP Rs 1347| Upside 15%
Investec maintained a buy rating on Cipla but raised the target price to Rs 1550. Cipla's 10%+ fall from its 52-week high is in anticipation of Amneal's entry into 'albuterol' and a likely weak Q4.
Cipla's dependence on 'albuterol' is low and its impact on EPS is likely to be low.
The global investment bank sees the possibility of upgrades especially for FY25/26 as Cipla delivers key pipeline assets and US Gx macro continues to improve.
(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
Source: Stocks-Markets-Economic Times
